Key facts
- This page summarizes Viriom, Inc.'s Form 3 filing for Onconova Therapeutics, Inc. (TRAW).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Apr 2024, 19:57.
Viriom, Inc. - 03 Apr 2024 Form 3 Insider Report for Onconova Therapeutics, Inc. (TRAW)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TRAW
- Reported as of
- 03 Apr 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ VIRIOM, INC., By: Iain Dukes, Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Viriom, Inc. filed Form 3 for Onconova Therapeutics, Inc. (TRAW) on 03 Apr 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRAW
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,645,100
- Date
- 03 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRAW
holding
Derivative
Series C Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,011,144
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share ("Common Stock"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.
Footnote F2
Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.